
Orforglipron and the Pharmacology of Oral GLP-1 Receptor Agonism: What Makes Foundayo Different From Peptide-Based Incretin Therapy
Foundayo represents a different approach to GLP-1 therapy: a nonpeptide small molecule designed for oral administration. This review examines the pharmacology, clinical evidence, and implications of orforglipron.
· Peptimize Editorial





